2024
Bladder-sparing Therapy for Bacillus Calmette-Guérin–unresponsive Non–muscle-invasive Bladder Cancer: International Bladder Cancer Group Recommendations for Optimal Sequencing and Patient Selection
Li R, Hensley P, Gupta S, Al-Ahmadie H, Babjuk M, Black P, Brausi M, Bree K, Fernández M, Guo C, Horowitz A, Lamm D, Lerner S, Lotan Y, Mariappan P, McConkey D, Mertens L, Mir C, Ross J, O'Donnell M, Palou J, Pohar K, Steinberg G, Soloway M, Spiess P, Svatek R, Tan W, Taoka R, Buckley R, Kamat A. Bladder-sparing Therapy for Bacillus Calmette-Guérin–unresponsive Non–muscle-invasive Bladder Cancer: International Bladder Cancer Group Recommendations for Optimal Sequencing and Patient Selection. European Urology 2024 PMID: 39183090, DOI: 10.1016/j.eururo.2024.08.001.Peer-Reviewed Original ResearchNon-muscle-invasive bladder cancerInternational Bladder Cancer GroupBladder-sparing treatmentCarcinoma in situNadofaragene firadenovecRadical cystectomyBladder cancerOptimal selection of patientsAbsence of randomized trialsBladder-sparing therapySingle-agent chemotherapyBladder cancer groupSelection of patientsDevelopment of agentsPatient selectionSystemic toxicityCancer groupUnapproved agentsClinical trial participationPatient characteristicsRandomized trialsMitomycin CTumor attributesConsensus recommendationsCancer experts
2018
Intravesical device-assisted therapies for non-muscle-invasive bladder cancer
Tan W, Kelly J. Intravesical device-assisted therapies for non-muscle-invasive bladder cancer. Nature Reviews Urology 2018, 15: 667-685. PMID: 30254383, DOI: 10.1038/s41585-018-0092-z.Peer-Reviewed Original ResearchConceptsNon-muscle-invasive bladder cancerElectromotive drug administrationDevice-assisted therapiesBladder cancerHyperthermic chemotherapyDevice-assisted treatmentsIntravesical adjuvant treatmentHigh-risk diseaseResults of randomized trialsRisk of recurrenceRisk of progressionAlternative to BCGEffective treatment optionSingle-arm study designBladder cancer diagnosisBCG failureRandomized controlled trialsMaintenance regimensAdjuvant treatmentPatient cohortTreatment optionsRandomized trialsDrug AdministrationControlled trialsClinical guidelines